KRAS and neoplasm: Tumor cells with TP53 mutations or elevated replication stress—such as those harboring co-occurring KRAS and TP53 mutations, frequently seen in PDAC—become increasingly reliant on PKMYT1-mediated checkpoint control (Chen et al., 2022; Tornesello, 2025).